ICON Public Limited Company (ICLR) AI Stock Analysis

Founded in 1990 and based in Dublin, Ireland, ICON Public Limited Company operates as a clinical research organization delivering outsourced development and commercialization services globally. The company manages programs across the clinical development lifecycle, from compound selection through Phase I-IV trials. Its services include early development, patient recruitment, strategic analytics, late-phase research, and technology solutions. ICON also provides medical imaging, laboratory services, project management, site monitoring, data management, biostatistics, medical writing, pharmacovigilance, and regulatory support for pharmaceutical, biotechnology, and medical device clients, alongside consulting and advisory services.

ICON expanded annual revenue from $5.48B in FY2021 to $8.25B in FY2025, recording a 5-year revenue CAGR of 24.2% from FY2020 to FY2025. Annual net income peaked at $791.5M with a 9.6% net margin in FY2024 before decreasing to $229.3M with a 2.8% net margin in FY2025, as revenue declined 0.4%. Operating margin contracted from 13.3% in FY2024 to 12.3% in FY2025, while gross margin fell to 26.4%. In the trailing twelve months ended June 30, 2026, revenue totaled $8.29B with a profit margin of 0.3%. In the latest quarter, revenue grew 1.2% year-over-year, but earnings contracted 63.3%.

As of June 30, 2026, ICON held $928.4M in cash and short-term investments against $3.49B in total debt, resulting in net debt of $2.56B. The company maintained a current ratio of 0.95 and a debt-to-equity ratio of 0.37 against shareholders' equity of $9.38B. Operating cash flow reached $1.04B in FY2025, supporting free cash flow of $862.0M after capital expenditures of $174.2M. ICON deployed $750.0M toward share buybacks in FY2025, contributing to a 5-year share count change of -6.6%.

At a last close of $170.18 on October 16, 2026, ICON carries a market capitalization of $13.13B and an enterprise value of $15.21B. Its trailing P/E of 179.1x and forward P/E of 14.7x compare to 24.6x and 17.3x, respectively, for the median of its US-listed Healthcare peers. Its EV/EBITDA multiple of 22.8x is higher than the peer median of 12.0x, while its price-to-sales ratio of 1.6x sits below the peer median of 4.1x. Over the past year, ICON's stock delivered a return of -9.7%, trailing the S&P 500 (SPY) return of 16.8%.

Wall Street coverage consists of 9 Strong Buy, 1 Buy, and 8 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target of $187.76 represents a 10.3% premium over the last close of $170.18. For FY2026 ending December 31, 2026, analysts estimate revenue of $8.14B and EPS of $10.57, representing an EPS decline of 15.6%. Looking ahead to FY2027, 18 analysts project revenue of $8.43B and EPS of $11.78. ICON has beaten EPS expectations in 3 of the last 4 quarters, with its next earnings report scheduled for October 27, 2026.

This page is an AI-written research summary of ICON Public Limited Company (ICLR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ICLR income statement, ICLR balance sheet, ICLR key metrics, ICLR analyst forecast, ICLR chart. See the ICLR stock overview for the latest quote and news.